Genelux Quick Ratio (GNLX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Genelux Corporation  (NASDAQ: GNLX)

Genelux's Quick Ratio

GNLX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 2.05 below Genelux Corporation average.

Within Major Pharmaceutical Preparations industry 290 other companies have achieved higher Quick Ratio than Genelux in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 839 to 1390.

Explain Quick Ratio?
How much Cash & cash equivalents GNLX´s has?
What are GNLX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GNLX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 119.63 % -5.39 % -52.26 % -7.16 % 25.27 %
Y / Y Cash & cash equivalent Change 6.79 % -25.33 % -52.76 % -38.59 % -16.84 %
Quick Ratio MRQ 2.05 3.77 2.52 4.38 4.21
GNLX's Total Ranking # 1390 # 839 # 964 # 607 # 0
Seq. Current Liabilities Change 109.75 % 19.97 % 21.5 % -28.16 % -9.64 %
Seq. Cash & cash equivalent Change 13.97 % 79.58 % -30.22 % -25.23 % -20.31 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 291
Healthcare Sector # 502
Overall Market # 1390


Quick Ratio Statistics
High Average Low
6.63 3.54 0.01
(Sep 30 2024)   (Dec 31 2022)




Financial Statements
Genelux's Current Liabilities $ 15 Millions Visit GNLX's Balance sheet
Genelux's Cash & cash equivalent $ 30 Millions Visit GNLX's Balance sheet
Source of GNLX's Sales Visit GNLX's Sales by Geography


Cumulative Genelux's Quick Ratio

GNLX's Quick Ratio for the trailling 12 Months

GNLX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 2.68 % -19.27 % -18.47 % 18.59 % 7.58 %
Y / Y Cash & cash equivalent TTM Growth -28.46 % -32.91 % -26.31 % -8.88 % 5.03 %
Quick Ratio TTM 2.85 3.71 4.01 3.72 4.09
Total Ranking TTM # 3876 # 2787 # 2814 # 3010 # 0
Seq. Current Liabilities TTM Growth 32.88 % -1.61 % -20.53 % -1.18 % 4.48 %
Seq. Cash & cash equivalent TTM Growth 2.12 % -9.02 % -14.19 % -10.27 % -4.24 %

Quick ratio ranking by company, industry and sector >> Back to GNLX Financial Strength Comparisons >> Go to Compare GNLX Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $14.59 millions, cumulative Quick Ratio decreased to 2.85 above the GNLX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Genelux. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2787 to 3876.

Explain Quick Ratio?
How much Cash & cash equivalents GNLX´s has?
What are GNLX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 433
Healthcare Sector # 885
Within the Market # 3876


trailing twelve months Quick Ratio Statistics
High Average Low
2.78 1.69 1.01
(Mar 31 2024)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Adial Pharmaceuticals Inc   5.51 $ 28.200  Millions$ 5.121  Millions
Corbus Pharmaceuticals Holdings Inc   5.49 $ 117.941  Millions$ 21.483  Millions
Bio Green Med Solution Inc   5.48 $ 3.790  Millions$ 0.692  Millions
Arrowhead Pharmaceuticals Inc   5.47 $ 1,551.301  Millions$ 283.346  Millions
Context Therapeutics Inc   5.45 $ 42.990  Millions$ 7.885  Millions
Annexon Inc   5.44 $ 209.200  Millions$ 38.482  Millions
Arbutus Biopharma Corp  5.35 $ 19.172  Millions$ 3.585  Millions
Cns Pharmaceuticals Inc   5.35 $ 19.985  Millions$ 3.738  Millions
Neurogene Inc   5.23 $ 112.485  Millions$ 21.505  Millions
Lexaria Bioscience Corp   5.20 $ 3.642  Millions$ 0.701  Millions
Barinthus Biotherapeutics Plc  5.19 $ 59.295  Millions$ 11.423  Millions
Lite Strategy Inc   5.15 $ 5.706  Millions$ 1.109  Millions
Immuneering Corporation  5.14 $ 41.731  Millions$ 8.116  Millions
BlossomHill Therapeutics, Inc.  5.12 $ 95.376  Millions$ 18.621  Millions
Lyell Immunopharma Inc   5.12 $ 204.102  Millions$ 39.867  Millions
Altimmune inc   5.04 $ 63.008  Millions$ 12.501  Millions
Rani Therapeutics Holdings Inc   5.02 $ 53.391  Millions$ 10.638  Millions
Phio Pharmaceuticals Corp  4.99 $ 12.996  Millions$ 2.606  Millions
Immunic Inc   4.96 $ 155.098  Millions$ 31.260  Millions
Uniqure N v   4.96 $ 413.027  Millions$ 83.345  Millions
Silo Pharma Inc  4.90 $ 5.227  Millions$ 1.066  Millions
Apnimed, Inc.  4.86 $ 172.804  Millions$ 35.578  Millions
Atossa Therapeutics Inc   4.81 $ 26.204  Millions$ 5.451  Millions
Calcimedica Inc   4.71 $ 18.600  Millions$ 3.950  Millions
Kala Bio inc   4.70 $ 7.229  Millions$ 1.538  Millions
Septerna Inc   4.69 $ 372.322  Millions$ 79.316  Millions
Viking Therapeutics Inc   4.57 $ 501.663  Millions$ 109.656  Millions
Camp4 Therapeutics Corporation  4.51 $ 86.398  Millions$ 19.142  Millions
Rein Therapeutics Inc   4.49 $ 43.627  Millions$ 9.709  Millions
Quantum Cyber N v   4.46 $ 13.415  Millions$ 3.005  Millions

Date modified: 2026-10-05T11:03:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.